Veklury (remdesivir)

Product description

Brand name
Veklury
Company name
Gilead Sciences Canada Inc
Ingredient
remdesivir
Date of approval

Resources

Click on a resource to visit a page with more information. You may be taken away from this page to a different Government of Canada website.

Updated Date Resources for Resources Description Date
Consumers, Health Care Professionals

Information about the product including what the product is used for, dosage, warnings, proper use and side effects.  This summary will not tell you everything about the product. Contact your healthcare professional if you have any questions about the product.

Health Care Professionals, Researchers

The Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use.

The Product Monograph includes three sections:

  • Part I: Health Professional Information;
  • Part II: Scientific Information; and
  • Patient Medication Information

 

Consumers

The Regulatory Decision Summary explains Health Canada’s decision for the product seeking market authorization. The RDS includes the purpose of the submission and the reason for the decision.

Health Care Professionals, Researchers

The Summary Basis of Decision explains why the product was approved for sale in Canada. The document includes regulatory, safety, effectiveness and quality (in terms of chemistry and manufacturing) considerations.

Consumers, Health Care Professionals

Summary Safety Review - Assessing the Potential Risks of Acute Kidney Injury (AKI) and Acute Renal Failure (ARF)

A Summary Safety Review complements other safety related information to help Canadians make informed decisions about their use of health products. Each summary outlines what was assessed in Health Canada’s review, what was found and what action was taken by Health Canada, if any.

Consumers, Health Care Professionals

Summary Safety Review - Assessing the Potential Risk of Sinus Bradycardia

A Summary Safety Review complements other safety related information to help Canadians make informed decisions about their use of health products. Each summary outlines what was assessed in Health Canada’s review, what was found and what action was taken by Health Canada, if any.

Health Care Professionals, Researchers

The Post Authorization Activity Table includes brief summaries of the activities that occur after the approval of the product. It is updated on a monthly basis.

Researchers

After Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.

Health Care Professionals, Researchers

For COVID-19 authorizations, Health Canada can impose specific terms and conditions on the authorization. This allows Health Canada to continue to gather information on the safety, effectiveness and/or quality of the product as more studies are completed.

Consumers, Health Care Professionals, Researchers

Advisories are published when Health Canada has important updates or other information to share about the product, such as information on new approvals, shortages, labelling updates, or risks.

Clicking the link will retrieve any advisories Health Canada has issued about the product. If no advisories have been issued, no results will be returned.

Various
Consumers, Health Care Professionals

An update from Health Canada on the continued monitoring of the use of remdesivir for COVID-19.

Regulatory Announcements